Wound care providers across the nation have felt the impact of increased scrutiny by the Centers for Medicare & Medicaid Services (CMS) and the drastically reduced reimbursements for skin grafts. On January 1, 2026, CMS implemented one of the most significant reimbursement recalibrations the wound care space has seen in years, slashing Medicare Physician Fee Schedule rates for skin substitute products and related applications by approximately 90%.
However, one thing CMS did not do is declare skin grafts experimental, regardless of what UPIC auditors, Medicare Administrative Contractors, and Quality Independent Contractors may be alleging in audits. It did not issue a national non-coverage determination but instead dropped the reimbursements considerably.
That distinction is not academic. It is the foundation of every audit defense, every appeal, and every compliance strategy in this space going forward.
In regulatory terms, what happened in 2026 is a repricing, not a repudiation. CMS recalibrated how it values these products and tightened the utilization lens through which it reviews claims. For providers now navigating a surge of post-payment audits, recoupment demands, and heightened scrutiny, understanding this distinction is essential.
When CMS continues to reimburse a category of products, even at dramatically lower rates, it implicitly confirms that the category remains within the scope of “reasonable and necessary” care under §1862(a)(1)(A) of the Social Security Act. A product that CMS still pays for is, by definition, not categorically excluded. Auditors who frame denials as though these products have been rendered non-covered are overreaching, and providers must fight back.
Current Legal Challenges
The litigation emerging from the skin substitute space in 2026 tells a story that is as much about procedural gatekeeping as it is about substantive policy.
In CAMPs Initiative v. HHS, filed in the Northern District of Texas, a coalition of manufacturers challenged CMS’s reimbursement reductions and classification changes head-on. The court dismissed the case, but not because CMS won on the merits. The dismissal was jurisdictional. The court held that the plaintiffs had not exhausted Medicare’s administrative review structure before seeking judicial intervention, a prerequisite that federal courts have enforced with remarkable consistency in the Medicare context. The substance of CMS’s policy decisions, including whether the reimbursement cuts were arbitrary and whether the reclassification was procedurally sound, was never reached.
A separate provider-led class action, also filed in the Northern District of Texas, takes aim at a related but distinct issue, specifically the alleged retroactive reclassification of skin substitute claims as “experimental or investigational,” which has triggered recoupments of claims that were previously paid without objection. This case remains in its early stages, and CMS is expected to raise similar jurisdictional defenses.
The pattern across both cases is instructive. Federal courts are not yet engaging with the merits of CMS’s policy shifts in this space. They are resolving cases at the threshold, reinforcing a principle that wound care providers must internalize: the administrative appeals process is not a waystation on the road to federal court. For the foreseeable future, it is the destination. Providers who treat it as an afterthought, filing perfunctory appeals while pinning their hopes on judicial intervention, are making a strategic miscalculation.
Documentation is More Important than Ever
In this new enforcement environment, providers with the best documentation will weather audits more successfully than their peers.
The Administrative Law Judge (ALJ) level remains the most likely forum for meaningful success. It is at the ALJ level, the third level of the CMS administrative appeals process, that the quality of the clinical record is often dispositive. Providers who present well-developed evidentiary records, including detailed wound progression notes, clear articulation of clinical rationale for product selection, documented failure of alternative therapies before escalation, and consistency across treatment episodes, are seeing materially stronger outcomes. Those who rely on templated notes, sparse documentation, or after-the-fact reconstructions are not.
Several principles should guide providers in this environment. First, coverage status remains a powerful anchor in any defense. If CMS pays for a service, even at reduced rates, the argument that it is “not reasonable and necessary” faces an inherent logical barrier absent an explicit exclusion. Second, the appeals process demands investment. Given the procedural barriers that have stalled federal court litigation, providers must treat administrative appeals with the seriousness and resource commitment they would bring to any high-stakes proceeding. Third, compliance programs must evolve in real time. The CMS landscape in this space is not static. Local Coverage Determination (LCD) guidance is shifting, utilization benchmarks are tightening, and the enforcement posture of audit contractors is becoming more aggressive. Providers who are still operating under pre-2026 assumptions are exposed.
Reimbursement Policy Over Coverage Determinations
What is happening in the skin substitute space is not unique. It reflects a broader CMS posture of using reimbursement policy, rather than coverage determinations, as the primary lever for controlling utilization and cost in areas where clinical evidence is evolving. CMS is not saying these products do not work. It is saying it wants to pay less for them and scrutinize more carefully how they are used. For instance, many UPIC auditors will state in their denial of services that the provider did not justify why a more cost-effective option was not used instead of skin grafts that are more costly.
For providers, this creates a paradox. The products remain covered, but the economics of delivering them have changed dramatically. The margin compression from reimbursement cuts, combined with the compliance costs of defending against audits, is reshaping the operational calculus for wound care practices. Some providers will exit the space. Others will adapt by tightening their clinical protocols, investing in documentation infrastructure, and building the kind of audit-ready practices that can withstand scrutiny.
The litigation trajectory, meanwhile, suggests that manufacturers and providers are converging on similar legal theories, primarily focused on due process and retroactivity concerns, but that meaningful judicial engagement with these arguments remains months or years away. In the interim, the administrative appeals system will continue to be the forum where individual provider outcomes are determined.
The Road Ahead
In 2019, it was reported that Medicare Part B payments for skin graft products were approximately $256 million. Part B payments for skin grafts were reported to have increased nearly 40-fold to $9.9 billion in 2024. Although 2025 numbers are not out yet, it is projected that between $15 billion and $16 billion was spent on skin grafts by Medicare Part B.
The wound care and skin substitute market in 2026, and beyond, is going to experience a significant amount of auditing since CMS is allowed to claw back four years from the date of payment. For calendar years 2024 and 2025 alone, CMS has approximately $25 billion of potential recoveries that it can target through 2028-2029.
Along the same lines, CMS is adamant about not paying 2025 claims submitted in 2026. Providers who relied on CMS’ “one year” rule to submit bills are experiencing Additional Document Requests (ADR) before paying any grafts at the old reimbursement rates. Not surprisingly, providers are seeing ADR requests being routinely denied as not medically reasonable and necessary, requiring them to appeal the denial and chase CMS for payment.
How Frier Levitt Can Help
At Frier Levitt, we are actively representing providers across the country in skin substitute audits and appeals, including ADR denials and pre-payment reviews. The landscape is evolving rapidly, but the core message remains consistent: these products are covered, their use is defensible, and the providers who work with healthcare counsel and trusted advisors are well-positioned to weather this storm.
If your practice is facing an audit, recoupment demands, or is being refused payment after receiving an ADR, contact Frier Levitt today.
